UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the ~~Securities Exchange Act of 1934~~

~~Date~~Securities ofExchange ~~report~~Act ~~(Date~~ of ~~earliest event reported): December 11, 2025~~1934

Date of report (Date of earliest event reported): February 6, 2026

Roivant Sciences Ltd.

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its charter~~Charter)

Bermuda	~~001-40782~~	~~98-1173944~~	001-40782	98-1173944
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(I.R.S. Employer Identification No.)

7th Floor

50 Broadway

London SW1H 0DB

United Kingdom

~~(Address~~1 ofPennsylvania ~~principal executive offices, and Zip Code)~~Plaza

~~+44~~Floor ~~207 400-3347~~54

New York, NY
101191

Viaduktstrasse 8

4051 Basel

Switzerland1

(Addresses of Principal Executive Offices, and Zip Code)

+44 207 400 3347

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former ~~name~~Name or ~~former~~Former ~~address~~Address, if ~~changed~~Changed ~~since~~Since ~~last~~Last ~~report~~Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


			o			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

			o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

			o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

			o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, $0.0000000341740141 per share

ROIV

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐o

~~Item~~1 ~~7.01.~~Addresses ~~Regulation~~of FDwholly-owned ~~Disclosure~~subsidiaries of the Registrant.

OnItem ~~December 11, 2025, Roivant Science Ltd~~2. ~~(the “Company”) issued a press release in connection with the Company’s 2025 Investor Day~~02. Results ~~A copy~~ of ~~the~~Operations ~~press release is attached as Exhibit 99.1 to this Current Report on Form 8-K~~ and isFinancial ~~incorporated herein by reference~~Condition.

~~Also~~On onFebruary ~~December 11~~6, ~~2025~~2026, ~~the~~Roivant ~~Company~~Sciences ~~posted~~Ltd. (the ~~presentation~~“Company”) toissued bea ~~used~~press inrelease ~~connection~~announcing ~~with~~ its ~~2025~~financial ~~Investor~~results ~~Day~~for on the ~~“Events~~fiscal &quarter ~~Presentations”~~ended ~~page~~December of31, ~~its investor relations website at https://investor~~2025.~~roivant.com.~~ A copy of the ~~presentation~~press release is attached as Exhibit 99.21 to this Current Report on Form 8-K ~~and is incorporated herein by reference~~. ~~The contents of the Company’s website referenced in this Current Report on Form 8-K are not incorporated into this Current Report on Form 8-K.~~

The information ~~furnished~~set forth under this “Item 72.~~01,~~02. ~~including~~Results ~~Exhibits~~of ~~99.1~~Operations and Financial Condition” (including Exhibit 99.2,1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, oras ~~subject~~amended, tonor ~~the~~shall ~~liabilities~~it ofbe ~~that~~incorporated ~~section~~by orreference ~~Sections~~in 11any ~~and~~filing ~~12(a)(2)~~made ofby the Company pursuant to the Securities Act of 1933., ~~The~~as ~~information in this Item 7.01~~amended, ~~including~~other ~~Exhibits~~than ~~99.1~~to ~~and~~the ~~99.2,~~extent ~~shall~~that ~~not~~such befiling ~~deemed~~incorporates ~~incorporated~~ by reference ~~into~~ any ~~other filing with the U.S. Securities Exchange Commission made by the Company, whether made before~~ or ~~after~~all ~~the date hereof, regardless~~ of ~~any~~such ~~general~~information ~~incorporation~~by ~~language~~express inreference ~~such filing~~thereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	~~Description of Exhibit~~	Description of Exhibit
99.1	~~Press release dated December 11, 2025.~~	Roivant Science Ltd. Press Release, dated February 6, 2026
99.2	Presentation dated December 11, 2025.
104		Cover Page Interactive Data File (embedded with Inline XBRL document)
104	Cover Page Interactive Data File (embedded with Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROIVANT SCIENCES LTD.
By:	~~/s/ Keyur Parekh~~	/s/ Keyur Parekh
Name: Keyur Parekh
Title: Authorized Signatory
Dated: December 11, 2025
Dated: February 6, 2026

Filing Compare · Roivant Sciences Ltd.